Crowley C, Winship A Z, Hawkins M A, Morris S L, Leslie M D
Department of Clinical Oncology, Guy's and St Thomas' Hospitals, London, UK.
Clin Oncol (R Coll Radiol). 2009 Jun;21(5):376-9. doi: 10.1016/j.clon.2009.01.015. Epub 2009 Mar 17.
Chemoradiation is the standard of care for the treatment of anal canal cancer, with surgery reserved for salvage. For tumours with uninvolved inguinal nodes, it is standard to irradiate the inguinal nodes prophylactically, resulting in large field sizes, which contribute to acute and late toxicity. The aim of this single-centre retrospective study was to determine if, in selected cases, prophylactic inguinal nodal irradiation could be avoided.
Between August 1998 and August 2004, 30 patients with biopsy-proven squamous cell anal canal cancer were treated with chemoradiation using one phase of treatment throughout. A three-field beam arrangement was used without attempting to treat the draining inguinal lymph nodes prophylactically. The radiotherapy dose prescribed was 50Gy in 25 daily fractions over 5 weeks. Concomitant chemotherapy was delivered with the radiation using mitomycin-C 7-12mg/m(2) on day 1 and protracted venous infusional 5-fluorouracil 200mg/m(2)/day throughout radiotherapy.
All patients had clinically and radiologically uninvolved inguinal and pelvic nodes and all had primary lesions that were T3 or less. The median age at diagnosis was 65 years (range 41-84). The median follow-up was 41 months (range 24-113). The mean posterior field size was 14x15cm and the mean lateral field size was 12x15cm. All patients achieved a complete response. Ninety-four per cent of patients (28/30) were alive and disease free. The two patients who died did so of unrelated causes and were disease free at death. Four patients relapsed and all were salvaged with surgery; two for local disease requiring abdominoperineal resection, one with an inguinal nodal relapse requiring inguinofemoral block dissection and one for metastatic disease to the liver who underwent liver resection.
This single-centre retrospective study supports the treatment for selected cases of anal canal cancer with smaller than standard radiation fields, avoiding prophylactic inguinal nodal irradiation. Hopefully this will translate into reduced acute and late toxicity. In future studies we would suggest that consideration is given as to whether omission of prophylactic inguinal nodal irradiation for early stage tumours should be explored.
放化疗是肛管癌治疗的标准方案,手术仅用于挽救性治疗。对于腹股沟淋巴结未受累的肿瘤,预防性照射腹股沟淋巴结是标准做法,这会导致照射野较大,从而增加急性和晚期毒性。本单中心回顾性研究的目的是确定在某些病例中是否可以避免预防性腹股沟淋巴结照射。
1998年8月至2004年8月期间,30例经活检证实为肛管鳞状细胞癌的患者接受了全程单阶段放化疗。采用三野照射方案,未试图预防性治疗引流的腹股沟淋巴结。规定的放疗剂量为50Gy,分25次,每日1次,共5周。同步化疗在放疗期间进行,第1天使用丝裂霉素-C 7 - 12mg/m²,放疗全程持续静脉输注5-氟尿嘧啶200mg/m²/天。
所有患者临床和影像学检查显示腹股沟及盆腔淋巴结未受累,所有患者的原发灶均为T3或以下。诊断时的中位年龄为65岁(范围41 - 84岁)。中位随访时间为41个月(范围24 - 113个月)。后野平均大小为14×15cm,侧野平均大小为12×15cm。所有患者均达到完全缓解。94%的患者(28/30)存活且无疾病。死亡的2例患者死于无关原因,死亡时无疾病。4例患者复发,均通过手术挽救;2例因局部疾病需要腹会阴联合切除术,1例因腹股沟淋巴结复发需要腹股沟股部淋巴结清扫术,1例因肝转移接受肝切除术。
本单中心回顾性研究支持对部分肛管癌病例采用小于标准照射野的治疗方法,避免预防性腹股沟淋巴结照射。有望由此降低急性和晚期毒性。在未来的研究中,我们建议考虑是否应探索对早期肿瘤省略预防性腹股沟淋巴结照射的方法。